Status: Recruiting
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Terrence J Bradley, MDUpdated: Jan 8, 2026Locations: 1
Eligibility criteria
Total bilirubin ≤ 2 upper limit of normal (ULN) except in patients with Gilbert'... [+10]
Uncontrolled high blood pressure (i.e., systolic blood pressure > 180 mm Hg, dia... [+4]